Australia
Mesoblast announced that in a study of COVID-19 patients with moderate to severe acute respiratory distress syndrome, there was 83% survival with two intravenous infusions of the company’s experimental allogeneic mesenchymal stem cell candidate Ryoncil.
At least some of the concern is that without greater funding and coordination, the companies won’t be able to buy sufficient raw materials, continue production of existing drugs and quickly scale up their capacity to meet the demand of new drugs and older therapies around the world.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
A recent research article from Monash University in Australia showed that in a laboratory setting, the use of ivermectin, a decades-old drug approved to treat head lice infections as well as the treatment of some parasitic worms, inhibited the SARS-CoV-2 within 24 to 48 hours of treatment.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Results from the trial, which will begin dosing on April 6, aren’t likely until September.
Pharma and life sciences companies from across the globe provide updates on their pipelines and business.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced it has expanded its lab facilities by more than 30% to accommodate demand, mainly from US and APAC-based biotech companies.
PRESS RELEASES